In a report released yesterday, Ryan Zimmerman from BTIG maintained a Hold rating on Vericel (VCEL – Research Report). The company’s shares opened today at $36.06.
According to TipRanks, Zimmerman is a 5-star analyst with an average return of 8.9% and a 47.46% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Vericel, and Stryker.
Currently, the analyst consensus on Vericel is a Moderate Buy with an average price target of $42.50, which is a 17.86% upside from current levels. In a report released on December 21, Truist Financial also maintained a Hold rating on the stock with a $39.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
VCEL market cap is currently $1.7B and has a P/E ratio of -161.79.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VCEL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel (VCEL) Company Description:
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Read More on VCEL:
- Vericel price target raised to $39 from $33 at Truist
- Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
- Vericel raises 2023 revenue view $192.5M-$197.5M from $190M-$197M
- Vericel reports Q3 EPS (8c), consensus (12c)
- Vericel to Present at the Stephens Annual Investment Conference
